WO1996022760A3 - Antagonists of alpha-melanocyte stimulating hormone and methods based thereon - Google Patents

Antagonists of alpha-melanocyte stimulating hormone and methods based thereon Download PDF

Info

Publication number
WO1996022760A3
WO1996022760A3 PCT/US1996/000404 US9600404W WO9622760A3 WO 1996022760 A3 WO1996022760 A3 WO 1996022760A3 US 9600404 W US9600404 W US 9600404W WO 9622760 A3 WO9622760 A3 WO 9622760A3
Authority
WO
WIPO (PCT)
Prior art keywords
stimulating hormone
melanocyte stimulating
antagonists
alpha
methods based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/000404
Other languages
French (fr)
Other versions
WO1996022760A2 (en
Inventor
J Mark Quillan
Channa K Jayawickreme
Michael R Lerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP8522891A priority Critical patent/JPH10512580A/en
Priority to AU46977/96A priority patent/AU722061B2/en
Priority to EP96902655A priority patent/EP0804217A4/en
Priority to BR9607178-8A priority patent/BR9607178A/en
Publication of WO1996022760A2 publication Critical patent/WO1996022760A2/en
Publication of WO1996022760A3 publication Critical patent/WO1996022760A3/en
Priority to MXPA/A/1997/005433A priority patent/MXPA97005433A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptide antagonists of α-melanocyte stimulating hormone are disclosed, together with methods of inhibiting the effects of α-melanocyte stimulating hormone or cells or tissues sensitive to that hormone. In particular, methods for lightening the pigmentation of skin and for treating malignant melanoma, as well as kits for practicing the invention are also disclosed.
PCT/US1996/000404 1995-01-17 1996-01-16 Antagonists of alpha-melanocyte stimulating hormone and methods based thereon Ceased WO1996022760A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP8522891A JPH10512580A (en) 1995-01-17 1996-01-16 Alpha-melanocyte stimulating hormone antagonists and methods based thereon
AU46977/96A AU722061B2 (en) 1995-01-17 1996-01-16 Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
EP96902655A EP0804217A4 (en) 1995-01-17 1996-01-16 Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
BR9607178-8A BR9607178A (en) 1995-01-17 1996-01-16 Hormone peptide antagonist stimulating alpha-melanocytes, processes for inhibiting hormone activity by stimulating alpha-melanocytes in a tissue or cell that responds to hormone by stimulating alpha-melanocytes, for clearing the complexation of an animal and for the treatment of melanoma malignant pharmaceutical composition and kit
MXPA/A/1997/005433A MXPA97005433A (en) 1995-01-17 1997-07-17 Antagonists of alpha-melanocyte stimulating hormone and methods based on myself

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/373,151 US6602856B1 (en) 1995-01-17 1995-01-17 Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
US373,151 1995-01-17

Publications (2)

Publication Number Publication Date
WO1996022760A2 WO1996022760A2 (en) 1996-08-01
WO1996022760A3 true WO1996022760A3 (en) 1996-09-26

Family

ID=23471196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/000404 Ceased WO1996022760A2 (en) 1995-01-17 1996-01-16 Antagonists of alpha-melanocyte stimulating hormone and methods based thereon

Country Status (7)

Country Link
US (1) US6602856B1 (en)
EP (1) EP0804217A4 (en)
JP (1) JPH10512580A (en)
AU (1) AU722061B2 (en)
BR (1) BR9607178A (en)
CA (1) CA2210737A1 (en)
WO (1) WO1996022760A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8912698A (en) * 1997-08-19 1999-03-08 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication using d-amino acid peptides
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
DE102006011883A1 (en) * 2006-03-09 2007-09-13 Beiersdorf Ag Tropolone- and hydroxybenzene-substituted oligopeptides for depigmentation
CN101795703B (en) * 2007-06-27 2015-05-06 里兰斯坦福初级大学理事会 Peptide tyrosinase inhibitors and uses thereof
KR20150083931A (en) * 2007-06-27 2015-07-20 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Oligopeptide tyrosinase inhibitors and uses thereof
JP6996042B2 (en) * 2016-09-15 2022-01-17 ディーエスエム アイピー アセッツ ビー．ブイ． New compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
IT1148005B (en) * 1981-04-09 1986-11-26 Leonida Grippa TRIPEPTIDE IN ITS SIX AMINO ACID COMBINATIONS ALANIA FENILALANINA AND LEUCINA IN PARTICULAR FENIL-ALANINA-ALANINA-LEUCINA (P-A-L) AVENTELA PROPERTY OF ENHANCING ANTIVIRAL AND ANTI-TUMORAL IMMUNITY
US4481139A (en) 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
IL74827A (en) 1984-05-21 1989-06-30 Salk Inst For Biological Studi Peptides active as gnrh antagonists and pharmaceutical compositions containing them
US5003011A (en) 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
DE3619633A1 (en) * 1986-06-11 1987-12-17 Hoechst Ag PEPTIDES WITH INFLUENCE ON DIURESE AND NATURALSE, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THEIR USE
WO1988007551A2 (en) 1987-03-31 1988-10-06 Imperial Cancer Research Technology Limited Growth factor receptor
US5081586A (en) * 1990-02-20 1992-01-14 Eaton Corporation Multiplexing of accessories in a vehicle

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, Volume 269, JAYAWICKREME et al., "Discovery and Structure Function Analysis of Alpha-Melanocyte-Stimulating Hormone Antagonists", pages 29846-29854. *
See also references of EP0804217A4 *

Also Published As

Publication number Publication date
AU4697796A (en) 1996-08-14
JPH10512580A (en) 1998-12-02
US6602856B1 (en) 2003-08-05
EP0804217A2 (en) 1997-11-05
EP0804217A4 (en) 1999-09-01
WO1996022760A2 (en) 1996-08-01
MX9705433A (en) 1997-11-29
AU722061B2 (en) 2000-07-20
CA2210737A1 (en) 1996-08-01
BR9607178A (en) 2004-10-19

Similar Documents

Publication Publication Date Title
AU4157397A (en) Compositions and methods for skin tanning and protection
ZA977513B (en) Skin tanning compositions and method.
EP1418235A3 (en) Intracellular domain of the her-2/neu protein for prevention or treatment of maligancies
WO1999004752A3 (en) Methods for treating skin pigmentation
IL131543A (en) Cosmetic methods and compositions for preventing and treating chronological aging in human skin
CA2281684A1 (en) Inhibition of cell-cell binding by lipid assemblies
IL134842A0 (en) Method of delivering genes to antigen presenting cells of the skin
SI1131039T1 (en) Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress
AU5627999A (en) Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution)
PL337531A1 (en) Compositions for and methods of inhibiting photo-ageing of skin
WO1996035784A3 (en) Chromatin-regulator genes
AU1939200A (en) Electrochemical treatment of malignant tumors
DE69839529D1 (en) EXPRESSION VECTORS AND CELL LINES FOR EXPRESSING VASCULAR GROWTH FACTOR D, AND METHOD FOR TREATING MELANOMA
AU5414996A (en) Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
DK0771147T3 (en) Compositions and Methods for Enhanced Tumor Cell Immunity in vivo
ATE280826T1 (en) CC CHEMOKINCEPTOR C-C CKR-5, DERIVATIVES THEREOF AND USES
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
WO2000002544A3 (en) Use of piperine for treating skin pigmentation disorders
PL312492A1 (en) Cosmetic composition based on guar rubber and silicones
ZA200005413B (en) Cholesterol sulfate compositions for enhancement of stratum corneum function.
WO1996022760A3 (en) Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
AU1395499A (en) Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells
ZA200006300B (en) Composition comprising tumor cells and extracts and method of using thereof.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96192639.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LS LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN AZ BY KG KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2210737

Country of ref document: CA

Ref document number: 2210737

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1996 522891

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/005433

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1996902655

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996902655

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996902655

Country of ref document: EP